论文部分内容阅读
目的:探讨大剂量布地奈德混悬液雾化吸入联合孟鲁司特对儿童哮喘的疗效及对血清中IL-1β和IL-6影响。方法:180例哮喘患儿随机分为观察组(90例)与对照组(90例),观察组在常规治疗基础上应用大剂量布地奈德混悬液雾化吸入联合孟鲁司特治疗,对照组在常规治疗基础上应用小剂量布地奈德混悬液雾化吸入联合孟鲁司特治疗。观察其疗效及治疗前、治疗后血清中IL-1β和IL-6的变化,比较其差异。结果:观察组疗效明显优于对照组。观察组与对照组在治疗后血清中IL-1β和IL-6的表达均较治疗前明显降低,但观察组治疗后的下降值明显高于对照组。结论:大剂量布地奈德混悬液雾化吸入联合孟鲁司特治疗儿童哮喘效果明显,且能对血清中IL-1β和IL-6有重要的调节作用,临床中可以积极应用。
Objective: To investigate the effect of high dose budesonide suspension inhalation combined with montelukast on children asthma and its influence on IL-1β and IL-6 in serum. Methods: One hundred and eighty children with asthma were randomly divided into observation group (n = 90) and control group (n = 90). The observation group was treated with high dose budesonide suspension inhalation combined with montelukast on the basis of routine treatment, The control group was treated with low-dose budesonide suspension aerosol inhalation combined with montelukast on the basis of routine treatment. To observe the curative effect and the changes of IL-1βand IL-6 in serum before treatment and after treatment, and to compare the differences. Results: The observation group was significantly better than the control group. The serum levels of IL-1β and IL-6 in observation group and control group were significantly lower than those before treatment, but the decrease in observation group was significantly higher than that in control group. Conclusion: High-dose budesonide suspension inhalation combined with montelukast treatment of children with asthma significantly, and can play an important regulatory role in serum IL-1β and IL-6, which can be actively used in clinical practice.